NewAmsterdam Pharma Company N.V. and the Menarini Group have received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending marketing authorization for Ubeslo, a 10 mg obicetrapib tablet, and Evlarco, a fixed-dose tablet containing 10 mg obicetrapib and 10 mg ezetimibe. The recommended indications cover adults with primary hypercholesterolaemia, including heterozygous familial and non-familial disease, or mixed dyslipidaemia who require additional low-density lipoprotein cholesterol reduction.
The opinion adopted on July 23, 2026 represents the most important European regulatory advance so far for NewAmsterdam Pharma’s lead cardiovascular programme. It does not, however, constitute final marketing authorization. The European Commission must review the recommendation before a centralized authorization can become valid across European Union member states and the wider European Economic Area, with the companies expecting a decision during the second half of 2026.
For NewAmsterdam Pharma, the decision reduces a major element of regulatory uncertainty surrounding obicetrapib’s ability to lower cholesterol. The remaining strategic question is broader and more commercially consequential: whether lowering low-density lipoprotein cholesterol through cholesteryl ester transfer protein inhibition will translate into fewer major cardiovascular events. That question is being examined separately in the Phase 3 PREVAIL cardiovascular outcomes trial and was not resolved by the CHMP opinion.
What exactly has the CHMP recommended for Ubeslo and Evlarco in Europe?
Ubeslo has been recommended as an adjunct to diet for adults with primary hypercholesterolaemia or mixed dyslipidaemia. The proposed indication includes use with a statin, or a statin plus other lipid-lowering treatments, when patients cannot reach their low-density lipoprotein cholesterol goals on the maximum tolerated statin dose. It would also allow obicetrapib to be used alone or with other lipid-lowering therapies when a statin is contraindicated or cannot be tolerated.
Evlarco has a more specifically defined role. The fixed-dose combination has been recommended for patients who remain above their cholesterol goals despite receiving the maximum tolerated statin dose together with ezetimibe. It could also be used without a statin in appropriate statin-intolerant patients who remain inadequately controlled on ezetimibe, as well as in patients already receiving obicetrapib and ezetimibe as separate tablets.
The distinction gives Menarini two possible commercial entry points. Ubeslo offers flexibility for prescribers who want to add a new oral mechanism to an existing regimen, while Evlarco packages two complementary cholesterol-lowering mechanisms into one daily tablet. That formulation could simplify treatment for selected patients, although convenience alone will not determine use. Pricing, reimbursement, physician familiarity and how the products are positioned within European treatment pathways will also shape uptake.
How strong was the Phase 3 evidence supporting the positive obicetrapib opinion?
The Ubeslo application was supported principally by the Phase 3 BROADWAY and BROOKLYN studies, while the Evlarco submission relied on the Phase 3 TANDEM trial. All three were randomized, double-blind studies evaluating additional cholesterol reduction in patients whose levels remained inadequately controlled despite background lipid-lowering treatment.
BROADWAY enrolled 2,530 participants with heterozygous familial hypercholesterolaemia or a history of atherosclerotic cardiovascular disease who were already receiving maximum tolerated lipid-modifying therapy. Participants were randomized in a two-to-one ratio to receive obicetrapib 10 mg or placebo for one year.
At day 84, the least-squares mean change in low-density lipoprotein cholesterol was a reduction of 29.9% in the obicetrapib group compared with an increase of 2.7% in the placebo group. The placebo-adjusted difference was 32.6 percentage points and was statistically significant. The published study reported that the overall incidence of adverse events appeared similar between the treatment and placebo groups.
BROOKLYN examined a smaller but more concentrated population of 354 patients with heterozygous familial hypercholesterolaemia. These patients had a mean baseline low-density lipoprotein cholesterol level of approximately 122 mg per decilitre despite maximally tolerated treatment, with 87% receiving statins.
Obicetrapib produced a placebo-adjusted low-density lipoprotein cholesterol reduction of 36.3% at day 84. The trial also reported reductions in apolipoprotein B, non-high-density lipoprotein cholesterol and lipoprotein(a), while high-density lipoprotein cholesterol increased substantially. The trial publication described obicetrapib as well tolerated, although the broader clinical meaning of changes in secondary lipid markers must be interpreted separately from the demonstrated low-density lipoprotein cholesterol effect.
Together, BROADWAY and BROOKLYN establish a repeatable cholesterol-lowering effect in different high-risk populations. Their randomized designs, placebo controls and 52-week exposure strengthen the evidence supporting the pharmacological effect. They do not independently demonstrate that obicetrapib prevents heart attacks, strokes or cardiovascular deaths.
Why could Evlarco become commercially important beyond obicetrapib monotherapy?
TANDEM enrolled 407 participants with established or elevated risk of atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolaemia. Participants received Evlarco, obicetrapib alone, ezetimibe alone or placebo for 84 days.
The fixed-dose combination produced a placebo-adjusted low-density lipoprotein cholesterol reduction of 48.6%. It also lowered cholesterol by 27.9% more than ezetimibe alone and by 16.8% more than obicetrapib monotherapy. Obicetrapib alone reduced low-density lipoprotein cholesterol by 31.9% compared with placebo in the same study.
Those findings explain why the combination could become the more commercially differentiated product. European clinicians frequently need to combine therapies when statins alone do not achieve risk-based cholesterol goals. A single tablet containing two non-statin mechanisms could reduce pill burden compared with prescribing obicetrapib and ezetimibe separately.
However, the TANDEM safety results deserve precise interpretation. Adverse events occurred in 51% of patients receiving the fixed-dose combination, 54% receiving obicetrapib, 53% receiving ezetimibe and 37% receiving placebo. Serious adverse events occurred in between 3% and 7% across the four groups, and one death occurred in each active-treatment group, with none in the placebo group. The published report did not establish that the deaths were caused by the study treatments, and the overall serious adverse event frequencies were described as generally similar.
The European Medicines Agency identifies hypertension, dizziness, headache, diarrhoea and abdominal pain among the most common adverse effects anticipated for both Ubeslo and Evlarco. Final prescribing details, including warnings, contraindications and adverse-reaction frequencies, will become clearer when the product information is published following any European Commission authorization.
Why does PREVAIL remain the decisive clinical test after the CHMP recommendation?
Low-density lipoprotein cholesterol is a well-established therapeutic target, and current European guidance continues to recommend statins as the first treatment choice while adding non-statin therapies when patients cannot reach their goals or cannot tolerate sufficient statin intensity. The existing options include ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors and bempedoic acid, each supported by varying levels of cardiovascular outcomes evidence.
Obicetrapib’s regulatory package demonstrates that it lowers low-density lipoprotein cholesterol. What the programme still needs is direct confirmation that adding obicetrapib reduces cardiovascular events in the intended population.
PREVAIL has randomized more than 9,500 patients and is designed to measure major adverse cardiovascular events. NewAmsterdam Pharma began the study in March 2022 and completed enrolment in April 2024. The company has planned an interim analysis during the fourth quarter of 2026, with the result expected during the first quarter of 2027. If the trial does not stop early for efficacy, completion has been projected for the end of 2027.
A successful outcomes trial could materially strengthen obicetrapib’s clinical positioning and support broader confidence among prescribers, payers and guideline committees. An inconclusive or unsuccessful result would make Ubeslo and Evlarco more dependent on their cholesterol-lowering performance, tolerability, convenience and cost rather than demonstrated cardiovascular-event reduction.
That distinction also matters commercially. Established non-statin treatments already compete for patients who remain above cholesterol targets. Obicetrapib does not merely need to lower low-density lipoprotein cholesterol. It must secure a practical place within treatment escalation strategies that are becoming increasingly crowded.
How does the Menarini partnership affect the commercial opportunity in Europe?
Menarini holds exclusive European commercialization rights for obicetrapib as both monotherapy and a fixed-dose combination with ezetimibe. The privately held pharmaceutical group is also responsible for regional regulatory interactions and launch activities, allowing NewAmsterdam Pharma to participate economically without building an independent pan-European commercial organization.
NewAmsterdam Pharma is entitled to tiered royalties ranging from the low double-digit percentages to the mid-twenties on net sales in the Menarini territory. It may also receive up to an additional €833 million in clinical, regulatory and commercial milestone payments. Those figures represent potential payments, not revenue already earned, and their realization depends on defined future events.
A positive European Commission decision could activate the next stage of that economic model. Menarini would then need to convert regulatory authorization into country-level pricing, reimbursement and physician adoption. European commercialization is rarely a single launch event because market access, formulary processes and reimbursement negotiations differ across individual countries.
The dual-product strategy could help segment that effort. Ubeslo may appeal where physicians prefer to tailor combination regimens, while Evlarco could be positioned for patients already requiring ezetimibe. The ultimate balance between the two products will depend on their authorized labels, pricing relationship and reimbursement treatment.
What does the CHMP opinion mean for NewAmsterdam Pharma shares and investor sentiment?
NewAmsterdam Pharma shares closed at approximately $30.55 on July 23, before the July 24 announcement. That level was roughly 6% below the June 24 closing price of $32.63 and remained below the company’s 52-week high of approximately $42.20, although it was well above the lower end of the 52-week range. Recent market-capitalization estimates have placed the company at around $3.6 billion to $3.7 billion.
The share-price context suggests investors had already assigned meaningful value to the probability of European regulatory success. The positive CHMP opinion removes an important downside scenario, but it does not settle the larger valuation question because obicetrapib remains the company’s central asset and PREVAIL remains its most consequential clinical catalyst.
NewAmsterdam Pharma reported $707.3 million in cash, cash equivalents and marketable securities at March 31, 2026. First-quarter research and development spending was $38 million, while the company recorded a quarterly net loss of $48.4 million. That balance provides substantial resources for its late-stage programme, but investors will continue to examine operating expenditure, manufacturing preparations and the timing of potential milestone and royalty income.
The CHMP outcome is therefore best understood as a regulatory de-risking event rather than the endpoint of the investment case. It increases the likelihood that NewAmsterdam Pharma and Menarini can establish a European commercial franchise, but investor sentiment will remain sensitive to the final European Commission decision, launch readiness, reimbursement progress and PREVAIL.
What milestones will determine whether Ubeslo and Evlarco fulfil their European potential?
The immediate milestone is the European Commission’s final decision. Approval would confirm the exact authorized indications and enable publication of the final product information, which will define dosing instructions, adverse reactions, contraindications and other conditions of use.
The next commercial milestones will involve product supply, country-level market access and Menarini’s launch sequencing. Oral dosing offers a practical attribute, but European uptake will depend on whether payers regard the additional cholesterol reduction as sufficiently valuable relative to established therapies and whether the products are placed favourably within treatment pathways.
Beyond Europe, NewAmsterdam Pharma is pursuing regulatory decisions in other jurisdictions and continuing additional Phase 3 studies, including REMBRANDT and RUBENS. Those programmes could expand the evidence base into further patient groups, but their contribution to the commercial profile will depend on completed results and subsequent regulatory assessment.
The positive CHMP opinion confirms that the European regulator considers the submitted quality, safety and efficacy package capable of supporting a favourable recommendation. The next phase is less straightforward. Ubeslo and Evlarco must secure final authorization, enter national reimbursement systems and demonstrate that an orally administered CETP inhibitor can earn a durable place alongside established cholesterol-lowering therapies.
PREVAIL will eventually provide the answer that cholesterol measurements alone cannot. Until those cardiovascular outcomes are available, the European recommendation is a substantial achievement, but not yet the final clinical or commercial verdict on obicetrapib.
